60 Degrees Pharmaceuticals, Inc. income statement

In fiscal 2025, 60 Degrees Pharmaceuticals, Inc. reported revenue of $1.0m, up 65.5% on the year before, operating income of −$7.8m (a -771.6% margin) and net income of −$7.4m, or −$11.73 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

60 Degrees Pharmaceuticals, Inc.: income statement, annual
Fiscal year	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	223	254	608	1,005	1,111
Cost of revenue	432	475	385	782	895
Gross profit	−209	−221	223	224	216
Research and development	526	692	4,987	2,106	2,329
General and administrative	1,304	4,242	5,025	6,280	6,600
Operating income	−1,750	−5,155	−9,715	−7,759	−8,609
Interest expense	3,989	2,287	8	8	8
Net interest income	−4,427	1,341	—	—	—
Income before tax	−6,177	−3,814	−7,956	−7,368	−8,113
Income tax	1	0	0	0	—
Net income	−6,182	−3,766	−7,947	−7,365	−8,109
Diluted EPS	−$93.96	−$59.18	−$74.17	−$11.73	—
Diluted shares (average)	—	—	—	—	—
EBITDA	−1,723	−5,133	−9,703	−7,715	−8,548

US$ thousands unless shown otherwise. Fiscal quarters.

60 Degrees Pharmaceuticals, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	135	242	164	101	438	303	162	208
Cost of revenue	112	118	73	50	538	121	86	151
Gross profit	24	124	90	51	−100	183	76	57
Research and development	940	614	371	232	810	639	281	599
General and administrative	1,215	1,605	1,723	1,632	1,507	1,474	1,890	1,729
Operating income	−2,119	−2,065	−1,911	−1,606	−2,326	−1,917	−2,095	−2,271
Interest expense	1	1	2	1	2	3	1	1
Income before tax	−2,160	−2,050	−1,877	−1,735	−2,317	−1,441	−2,090	−2,266
Income tax	0	−1	0	2	0	−2	—	—
Net income	−2,160	−2,045	−1,877	−1,734	−2,316	−1,439	−2,089	−2,265
Diluted EPS	−$11.68	−$52.43	−$6.25	−$5.01	−$2.64	−$7.08	−$1.28	−$0.90
EBITDA	−2,114	−2,060	−1,904	−1,597	−2,313	−1,902	−2,078	−2,254

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: SXTC vs SXTP SCNX vs SXTP LPCN vs SXTP NTRB vs SXTP

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from 60 Degrees Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to 60 Degrees Pharmaceuticals, Inc.